Tilray Brands, Inc., Corbus Pharmaceuticals, and STENOCARE A/S are showing renewed momentum in the cannabis and biotech sectors. Tilray posted strong Q1 2025 results, Corbus received FDA Fast Track designation for its oncology programme, and Stenocare delivered one of its strongest Nordic quarters with share price gains over 120%. These developments highlight how operational progress, regulatory milestones, and market confidence are driving renewed investor attention. Which of these companies do you think has the most potential to maintain momentum through the rest of 2025? #CannabisIndustry #Stocks #CannabisBusiness
Tilray, Corbus, Stenocare: Cannabis and Biotech Sector Momentum
More from this author
Explore content categories
- Career
- Productivity
- Finance
- Soft Skills & Emotional Intelligence
- Project Management
- Education
- Technology
- Leadership
- Ecommerce
- User Experience
- Recruitment & HR
- Customer Experience
- Real Estate
- Marketing
- Sales
- Retail & Merchandising
- Science
- Supply Chain Management
- Future Of Work
- Consulting
- Writing
- Economics
- Artificial Intelligence
- Employee Experience
- Workplace Trends
- Fundraising
- Networking
- Corporate Social Responsibility
- Negotiation
- Communication
- Engineering
- Hospitality & Tourism
- Business Strategy
- Change Management
- Organizational Culture
- Design
- Innovation
- Event Planning
- Training & Development
🔗 https://businessofcannabis.com/speculation-to-selectivity-renewed-optimism-emerges-across-cannabis-and-biotech-plays/